Insider · CIK 0001548560
G. Michael Landis
Files at PLYX (Polaryx Therapeutics, Inc.). First filing Feb 20, 2026, latest Feb 20, 2026.
G. Michael Landis files SEC Form 4 as CFO and director at PLYX (Polaryx Therapeutics, Inc.). Since Feb 20, 2026, G. Michael Landis has reported 1 open-market buy worth $7,991 and 0 open-market sells worth $0, the latest filed on Feb 20, 2026.
A track record needs three past buys with six months of prices behind them; G. Michael Landis has 0, so none is measured yet.
The newest scored trade: bought $7,991 of PLYX on Feb 18, 2026, filed Feb 20, 2026, scored 22 (weak). In the last 12 months: 1 buy worth $7,991 and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
PLYX: Polaryx Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 22Weak | PLYXbuy Polaryx Therapeutics, Inc. | $7,991 2,867 shares | +1% | - |
Transactions
Every row this insider has filed, 1 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 18, 2026 | PLYX Polaryx Therapeutics, Inc. | POpen-market purchase Common Stock | +2,867 | $2.79 | $7,991 | 228,225 | Feb 20, 2026 |
Questions about G. Michael Landis
Answered from the filings on this page, as of the latest one.
Is G. Michael Landis buying or selling?
In the last 12 months G. Michael Landis reported 1 open-market buy worth $7,991 and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $7,991 of PLYX on Feb 18, 2026. Grants, option exercises and tax withholding are not counted.
How did G. Michael Landis's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and G. Michael Landis has 0.
Where does G. Michael Landis file Form 4?
G. Michael Landis has filed Form 4 at PLYX (Polaryx Therapeutics, Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.